A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Thomas E. Stinchcombe; Daniel S. Bradford; Thomas A. Hensing; Renato V. LaRocca; Mansoor Saleh; Tracey Evans; Kamal Bakri; Mark A. Socinski

doi:10.3109/07357900903286958

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Thomas E. Stinchcombe
, Daniel S. Bradford
, Thomas A. Hensing
, Renato V. LaRocca
, Mansoor Saleh
, Tracey Evans
, Kamal Bakri
, Mark A. Socinski

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

Original language	English (US)
Pages (from-to)	208-215
Number of pages	8
Journal	Cancer Investigation
Volume	28
Issue number	2
DOIs	https://doi.org/10.3109/07357900903286958
Publication status	Published - 2010
Externally published	Yes

Keywords

Clinical trial
Epidermal growth factor receptor (EGFR)
First-line therapy
Lung cancer
Platinum-based

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357900903286958

Cite this

@article{e84853c6da4941f58d6013917e98f47a,

title = "A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer",

abstract = "Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9\% (95\% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95\% CI, 1.9-3.6), the median overall survival was 8.2 months (95\% CI, 4.9-10.5), and 1-year survival rate was 33\% (95\% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.",

keywords = "Clinical trial, Epidermal growth factor receptor (EGFR), First-line therapy, Lung cancer, Platinum-based",

author = "Stinchcombe, \{Thomas E.\} and Bradford, \{Daniel S.\} and Hensing, \{Thomas A.\} and LaRocca, \{Renato V.\} and Mansoor Saleh and Tracey Evans and Kamal Bakri and Socinski, \{Mark A.\}",

year = "2010",

doi = "10.3109/07357900903286958",

language = "English (US)",

volume = "28",

pages = "208--215",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "2",

}

TY - JOUR

T1 - A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

AU - Stinchcombe, Thomas E.

AU - Bradford, Daniel S.

AU - Hensing, Thomas A.

AU - LaRocca, Renato V.

AU - Saleh, Mansoor

AU - Evans, Tracey

AU - Bakri, Kamal

AU - Socinski, Mark A.

PY - 2010

Y1 - 2010

N2 - Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

AB - Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

KW - Clinical trial

KW - Epidermal growth factor receptor (EGFR)

KW - First-line therapy

KW - Lung cancer

KW - Platinum-based

UR - https://www.scopus.com/pages/publications/77149127367

U2 - 10.3109/07357900903286958

DO - 10.3109/07357900903286958

M3 - Article

C2 - 19916742

AN - SCOPUS:77149127367

SN - 0735-7907

VL - 28

SP - 208

EP - 215

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this